Amphastar Pharmaceuticals, Inc. has unveiled plans to significantly expand its U.S.-based manufacturing operations, focusing on its headquarters in Rancho Cucamonga, California. The company announced it will quadruple its production capacity at this location within the next three to five years.
This initiative marks Amphastar’s most substantial infrastructure investment since its founding in 1996. The expansion will involve constructing a new, advanced manufacturing facility equipped with enhanced automation systems and modern technology. These developments aim to support the production of existing pharmaceutical products as well as pipeline candidates under development. Once operational, the upgraded facility is expected to generate new employment opportunities across several areas, including research and development, manufacturing, engineering, and quality operations.
The company has stated that this long-term strategy is aimed at boosting its domestic manufacturing capabilities while also contributing to supply chain resilience. Amphastar emphasized that all its finished pharmaceutical products are manufactured in the United States. Dr. Jack Zhang, President and CEO, stated, “Expanding our domestic manufacturing footprint is not only a strategic milestone for Amphastar but a reaffirmation of our commitment to producing essential medicines right here in the United States.”
According to the company, this expansion is designed to provide greater flexibility and efficiency in delivering its products to healthcare providers and patients. Amphastar plans to work in coordination with governmental entities to ensure the project aligns with broader economic and public health goals and to support ongoing workforce development.
The company, which has a 29-year history focused on complex injectable, inhalation, and intranasal products, is undertaking this expansion amid a downturn in financial performance. In the first quarter, Amphastar recorded revenue of $171 million, reflecting a decline both from the previous quarter and the same period in the prior year. Its key products include Baqsimi, a nasal powder medication for blood sugar emergencies, and Primatine MIST, an over-the-counter asthma inhaler. Baqsimi, which generated $38 million in revenue for the quarter, was acquired from Eli Lilly in 2023 for an upfront payment of $500 million, with an additional $575 million linked to future milestones. Primatine MIST brought in $29 million during the same quarter.
Amphastar’s decision to enhance its U.S. manufacturing infrastructure also comes as it faces declining revenue and a stock price that has reached its lowest point since 2021. In response, the company is placing increased emphasis on its proprietary pipeline, which includes biosimilar products, as it seeks to regain investor confidence.
Although the total investment amount has not been disclosed, the company reiterated that the capacity expansion is intended to “reinforce its commitment to domestic pharmaceutical manufacturing and strengthen supply chain resilience.” The planned facility will integrate expanded automation and advanced technologies to support both current commercial products and candidates under development.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
